Bladder cancer recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:13:32 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Bladder cancer recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Mycobacterium Bovis Bacillus Calmette-Guérin for High-risk Non-muscle Invasive Bladder Cancer Patients https://clinicaltrials.eu/trial/study-on-mycobacterium-bovis-bacillus-calmette-guerin-for-high-risk-non-muscle-invasive-bladder-cancer-patients/ Wed, 29 Apr 2026 15:02:33 +0000 https://clinicaltrials.eu/trial/study-on-mycobacterium-bovis-bacillus-calmette-guerin-for-high-risk-non-muscle-invasive-bladder-cancer-patients/ This clinical trial is focused on studying high-risk non-muscle invasive bladder cancer, a type of bladder cancer that has not spread into the muscle layer of the bladder but is considered high-risk due to its potential to progress. The treatment being tested is called IMUNO BCG Moreau RJ, which is a type of vaccine made from a live strain of bacteria known as Mycobacterium bovis Bacillus Calmette-Guérin, strain Moreau Rio de Janeiro. This treatment is used as a prophylactic, meaning it is intended to prevent the cancer from progressing further.

The purpose of the study is to assess how well patients with this type of bladder cancer respond to the treatment in terms of progression-free survival, which means the length of time during and after treatment that the patient lives with the disease without it getting worse. Participants in the study will receive the treatment through a method called intravesical use, where the solution is directly instilled into the bladder. The study will monitor patients over a period of time to see how the cancer responds to the treatment and to evaluate any side effects or adverse reactions that may occur.

Throughout the study, various aspects will be observed, including the rate at which the cancer progresses at 12 and 24 months, the overall survival without disease recurrence, and the quality of life of the participants. The study will also look at the body’s immune response to the treatment by analyzing certain proteins in the urine. This trial aims to provide valuable information on the effectiveness and safety of IMUNO BCG Moreau RJ in preventing the progression of high-risk non-muscle invasive bladder cancer.

]]>